| Literature DB >> 32457827 |
Hong Lu1,2, Nestor A Parra2, Jin Qi2, Kenneth Gage3, Qian Li1, Shuxuan Fan1,2, Sebastian Feuerlein3, Julio Pow-Sang4, Robert Gillies2,3, Jung W Choi3, Yoganand Balagurunathan3,4,5.
Abstract
Background: Multiparametric magnetic resonance imaging (mpMRI) has emerged as a non-invasive modality to diagnose and monitor prostate cancer. Quantitative metrics on the regions of abnormality have shown to be useful descriptors to discriminate clinically significant cancers. In this study, we evaluate the reproducibility of quantitative imaging features using repeated mpMRI on the same patients.Entities:
Keywords: mpMRI; prostate TRUS-MRI; prostate cancer; radiomics; repeatable MRI features; test–retest in mpMRI
Year: 2020 PMID: 32457827 PMCID: PMC7221156 DOI: 10.3389/fonc.2020.00551
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Screen capture of mpMRI prostate scan (A) with radiologist-marked lesion shown for the baseline and follow-up scans in T2w, (B) habitat converged with a sphere (15mm), and (C) habitat (≤ median) (in cyan) for a lesion (in red) shown for test and retest (along the rows) in T2w, ADC (along the column).
Summary of patient scans with clinical diagnosis for the biopsies.
| 1 | 1-b1 | Known Pca, staging | 5.4 | 3 + 4 | PZ | 4 | 4 | Identified |
| 2 | 1-b2 | NA | PZ | 4 | 4 | Additional | ||
| 3 | 2-b1 | Known Pca, assess change | 7.5 | 3 + 4 | PZ | 2 | 3 | Identified |
| 4 | 2-b2 | NA | PZ | 2 | 3 | Additional | ||
| 5 | 3 | Known Pca, staging | 8.2 | 3 + 3 | PZ | 4 | 4 | Identified |
| 6 | 4 | Known Pca, staging | 4.3 | 3 + 3 | PZ/TZ | 2 | 2 | Identified |
| 7 | 5-b2 | Suspected Pca, staging | NA | NA | TZ | 2 | 2 | Additional |
| 8 | 6-b2 | Elevated PSA, staging | 5 | Benign | TZ | 1 | 1 | Additional |
| 9 | 7 | Elevated PSA, staging | 6.2 | 4 + 5 | PZ | 4 | 4 | Identified |
| 10 | 8 | Known Pca, assess change | 4.8 | 4.8 | PZ | 4 | 4 | Identified |
| 11 | 9 | Elevated PSA, staging | 9.4 | Benign | PZ | 4 | 4 | Identified |
| 12 | 10 | Known Pca, assess change | 3.15 | 3 + 3 | PZ | 4 | 4 | Identified |
| 13 | 11 | Known Pca, assess change | 9.7 | 3 + 3 | PZ | 4 | 4 | Identified |
| 14 | 12 | Elevated Pca, staging | 5.5 | Benign | PZ | 3 | 4 | Identified |
| 15 | 13 | Known Pca, assess change | 4.16 | 3 + 4 | PZ | 4 | 3 | Identified |
| 16 | 14 | No biopsy performed | 7 | NA | NA | 2 | 2 | Ignored |
| 17 | 15 | Benign | 9.5 | Benign | NA | 1 | 2 | Ignored |
NA, biopsies pathological score not available or cannot be determined; Identified, identified abnormality as stated; Additional, additional abnormality; Ignored, unable to locate abnormality.
Distribution of quantitative imaging features at various levels of concordance and redundancy limits (Rsq at ≥0.99 and ≥0.95) for regions identified by (A) radiologist marked and (B) habitats converged (sphere), (C) habitat converged (≤ median, ADC map).
| ≥0.95 | 0 | 0 | 0 | 0 |
| ≥0.90 | 0 | 0 | 3 | 0 |
| ≥0.85 | 0 | 0 | 4 | 1 |
| ≥0.80 | 0 | 0 | 5 | 3 |
| ≥0.75 | 0 | 0 | 9 | 6 |
| ≥0.70 | 1 | 3 | 13 | 10 |
| ≥0.65 | 2 | 3 | 19 | 12 |
| ≥0.95 | 0 | 0 | 0 | 1 |
| ≥0.90 | 0 | 0 | 1 | 2 |
| ≥0.85 | 1 | 0 | 3 | 6 |
| ≥0.80 | 4 | 3 | 6 | 11 |
| ≥0.75 | 6 | 5 | 8 | 14 |
| ≥0.70 | 9 | 8 | 13 | 18 |
| ≥0.65 | 15 | 15 | 18 | 23 |
| ≥0.95 | 0 | 0 | 3 | 1 |
| ≥0.90 | 0 | 0 | 4 | 1 |
| ≥0.85 | 0 | 0 | 4 | 1 |
| ≥0.80 | 0 | 0 | 4 | 3 |
| ≥0.75 | 0 | 0 | 7 | 3 |
| ≥0.70 | 0 | 0 | 10 | 5 |
| ≥0.65 | 1 | 1 | 12 | 10 |
Radiomic features that show concordance and non-redundancy in the test–retest cohort (CCC and DR ≥ 0.65;Rsq ≥ 0.99) for (A) radiologist-marked region, (B) habitat region (sphere, 15 mm), (C) habitat (≤ median, ADC).
| F138:GLSZM_Large-zone-low-gray-level-emphasis- | F19:Stat-Root-Mn-Sq- |
| F47:Vol-at-Int-fraction-diff F43:Vol-at-Int-Fraction-10- | F47:Vol-at-Int-fraction-diff- F43:Vol-at-Int-Fraction-10- |
| F9:Stat-90th percentile | F96:avgCooc_3D_Difference-var |
| F228:3D-LawsF-R5-L5-L5-ADC-Auto | F302:3D-Wave-P1-L2-C13-ADC |
| F90:Border-length-(mm) | F52:Vol-(mm∧3)-ADC |
| F117:avg_3D_LRE-(Long-runs-emphasis)-ADC | F115:avgCooc_3D_Second-measure-of-information-correlation-ADC |
| F54:Surface-area-(mm∧2)- | F88:Center-of-mass-shift-(mm)-ADC |
| F10:Stat-Max-gray-level-ADC | F143:GLSZM_Zone-size-non-uniformity-normalized-ADCz-Auto |
| F93:avgCooc_3D_Joint-var-ADC-T2 | F3:Stat-SD-T2z |
Figure 2Repeatability of quantitative features across different lesion boundaries. (A) Concordance coefficient, (B) dynamic range.
Figure 3Concordance of quantitative features across feature subgroup. (A) T2w, (B) T2w z-normalized, (C) ADC, (D) ADC z-normalized.
Figure 4Dynamic range of quantitative features across feature subgroup. (A) T2w, (B) T2w z-normalized, (C) ADC, (D) ADC z-normalized.